UNION therapeutics
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
8.3%
1 terminated/withdrawn out of 12 trials
90.9%
+4.4% vs industry average
0%
0 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
Role: collaborator
Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
Role: lead
Study to Assess the Efficacy and Safety of Orismilast in Psoriasis
Role: lead
Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19
Role: lead
Orismilast for the Treatment of Mild to Severe Hidradenitis Suppurativa
Role: collaborator
Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers
Role: lead
Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD
Role: lead
A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers
Role: lead
Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
Role: lead
Sensitization Study of ATx201 in Healthy Volunteers
Role: lead
Evaluation of ATx201 as a Topical Antibiotic Agent
Role: lead
A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis
Role: lead
All 12 trials loaded